Utilización de medicamentos relacionados con el manejo de osteoartritis en Colombia: estudio descriptivo de corte transversal

IF 0.5 Q3 Health Professions

Revista Colombiana de Reumatologia Pub Date : 2026-04-01 Epub Date: 2025-11-12 DOI:10.1016/j.rcreu.2025.03.006

Miguel Eduardo Rubio Toloza , Manuel Enrique Machado Duque

{"title":"Utilización de medicamentos relacionados con el manejo de osteoartritis en Colombia: estudio descriptivo de corte transversal","authors":"Miguel Eduardo Rubio Toloza , Manuel Enrique Machado Duque","doi":"10.1016/j.rcreu.2025.03.006","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>The prevalence of osteoarthritis in the Colombian population is estimated at 10.8% and is associated with high health costs. The evaluation of the benefit-risk of the pharmacological treatment used is a fundamental aspect for all health professionals.</div></div><div><h3>Objective</h3><div>To identify the profile of medication use related to the management of osteoarthritis in adults over 50years of age in Colombia in 2022 and with an unfavourable benefit-risk ratio.</div></div><div><h3>Methods</h3><div>A quantitative, descriptive, cross-sectional study, taking into account all prescription dispensations of patients over 50years of age with a diagnosis of osteoarthritis, affiliated with the health plan of a Colombian insurer in 2022. The risk-benefit ratio was determined according to the <em>Prescrire</em> journal and the applicable STOPP criteria.</div></div><div><h3>Results</h3><div>A total of 18,824 patients were included, the median age found was 64years. Of these, 74.8% were women. The prevalence of prescription of medications related to osteoarthritis was 0.4% of all affiliates for the year 2022 by said insurer. The most prescribed medication was acetaminophen-codeine in 46.5% of patient dispensations. A total of 64.2% of users were prescribed drugs with an unfavourable benefit-risk ratio according to the <em>Prescrire</em> journal and STOPP criteria.</div></div><div><h3>Conclusions</h3><div>A significant proportion of prescriptions related to the management of osteoarthritis identified in this study contain at least one drug with an unfavourable benefit-risk ratio. This finding highlights the need to reflect on the optimization of prescribing, especially considering the chronic nature of osteoarthritis.</div></div>","PeriodicalId":37643,"journal":{"name":"Revista Colombiana de Reumatologia","volume":"33 2","pages":"Article 102182"},"PeriodicalIF":0.5000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Colombiana de Reumatologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S012181232500026X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/12 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Health Professions","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The prevalence of osteoarthritis in the Colombian population is estimated at 10.8% and is associated with high health costs. The evaluation of the benefit-risk of the pharmacological treatment used is a fundamental aspect for all health professionals.

Objective

To identify the profile of medication use related to the management of osteoarthritis in adults over 50 years of age in Colombia in 2022 and with an unfavourable benefit-risk ratio.

Methods

A quantitative, descriptive, cross-sectional study, taking into account all prescription dispensations of patients over 50 years of age with a diagnosis of osteoarthritis, affiliated with the health plan of a Colombian insurer in 2022. The risk-benefit ratio was determined according to the Prescrire journal and the applicable STOPP criteria.

Results

A total of 18,824 patients were included, the median age found was 64 years. Of these, 74.8% were women. The prevalence of prescription of medications related to osteoarthritis was 0.4% of all affiliates for the year 2022 by said insurer. The most prescribed medication was acetaminophen-codeine in 46.5% of patient dispensations. A total of 64.2% of users were prescribed drugs with an unfavourable benefit-risk ratio according to the Prescrire journal and STOPP criteria.

Conclusions

A significant proportion of prescriptions related to the management of osteoarthritis identified in this study contain at least one drug with an unfavourable benefit-risk ratio. This finding highlights the need to reflect on the optimization of prescribing, especially considering the chronic nature of osteoarthritis.

查看原文本刊更多论文

在哥伦比亚使用与骨关节炎管理有关的药物：横断面描述性研究

哥伦比亚人口中骨关节炎的患病率估计为10.8%，与高昂的医疗费用有关。对所使用的药理学治疗的利弊评估是所有卫生专业人员的一个基本方面。目的确定2022年哥伦比亚50岁以上成人骨关节炎治疗相关药物使用情况，并确定其不利的获益风险比。方法采用定量、描述性、横断面研究，纳入哥伦比亚一家保险公司2022年健康计划中诊断为骨关节炎的50岁以上患者的所有处方配药。风险收益比根据Prescrire杂志和适用的STOPP标准确定。结果共纳入18824例患者，中位年龄64岁。其中，74.8%为女性。该保险公司2022年与骨关节炎相关的处方药患病率为所有附属公司的0.4%。对乙酰氨基酚-可待因是处方最多的药物，占46.5%。根据Prescrire杂志和STOPP标准，共有64.2%的使用者处方的药物具有不利的获益-风险比。结论：在本研究中发现的与骨关节炎治疗相关的处方中，有相当大比例含有至少一种具有不利获益风险比的药物。这一发现强调需要反思处方的优化，特别是考虑到骨关节炎的慢性性质。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Colombiana de Reumatologia Medicine-Rheumatology

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The Colombian Journal of Rheumatology (Revista Colombiana de Reumatología) is the official organ of the Colombian Association of Rheumatology (Asociación Colombiana de Reumatología) and the Central American, Caribbean and Andean Association of Rheumatology (Asociación Centroamericana Caribe Andina de Reumatología) - ACCA. It was created in December 1993 with the purpose of disseminating scientific information derived from primary and secondary research and presenting cases coming from the practice of Rheumatology in Latin America. Since its foundation, the Journal has been characterized by its plurality with subjects of all rheumatic and osteomuscular pathologies, in the form of original articles, historical articles, economic evaluations, and articles of reflection and education in Medicine. It covers an extensive area of topics ranging from the broad spectrum of the clinical aspects of rheumatology and related areas in autoimmunity (both in pediatric and adult pathologies), to aspects of basic sciences. It is an academic tool for the different members of the academic and scientific community at their different levels of training, from undergraduate to post-doctoral degrees, managing to integrate all actors inter and trans disciplinarily. It is intended for rheumatologists, general internists, specialists in related areas, and general practitioners in the country and abroad. It has become an important space in the work of all rheumatologists from Central and South America.